Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers

Journal of Surgical Oncology

Volumn 111, Issue 7, 2015, Pages 905-910

  Lan, Yuan Tzu ^a,b   Jen Kou, Lin ^a,b   Lin, Chien Hsing ^b   Yang, Shung Haur ^a,b   Lin, Chun Chi ^a,b   Wang, Huann Sheng ^a,b   Chen, Wei Shone ^a,b   Lin, Tzu Chen ^a,b   Jiang, Jeng Kai ^a,b   Chang, Shih Ching ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

colorectal cancer; epidermal growth factor receptor; metastasis; signaling pathway

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; TUMOR MARKER;

AGED; ARTICLE; BONE METASTASIS; COLLOID CARCINOMA; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HETEROZYGOTE; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTATIC COLORECTAL CANCER; MICROSATELLITE INSTABILITY; MUTATIONAL ANALYSIS; NUCLEIC ACID ANALYSIS; ONCOGENE; ONCOGENE BRAF; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PERITONEUM METASTASIS; PI3K GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOMATIC MUTATION; WILD TYPE; CANCER STAGING; COLORECTAL TUMOR; FOLLOW UP; GENETICS; LUNG TUMOR; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY; TUMOR INVASION; TUMOR RECURRENCE;

AGED; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICROSATELLITE INSTABILITY; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; RAS PROTEINS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84928817166     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23895     Document Type: Article

References (35)

1. Galizia G, Lieto E, Ferraraccio F, et al.: Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 2006; 13: 823-835.
2. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al.: Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048.
3. Van Cutsem E, Kohne CH, Hitre E, et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
4. Lievre A, Bachet JB, Boige V, et al.: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-379.
5. Di Nicolantonio F, Martini M, Molinari F, et al.: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712.
6. Scaltriti M, Baselga J,: The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res 2006; 12: 5268-5272.
7. Neel NF, Martin TD, Stratford JK, et al.: The ralgef-ral effector signaling network: The road less traveled for anti-ras drug discovery. Genes & cancer 2011; 2: 275-287.
8. Yan C, Liu D, Li L, et al.: Discovery and characterization of small molecules that target the GTPase Ral. Nature 2014; 515: 443-447.
9. Perrone F, Lampis A, Orsenigo M, et al.: PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009; 20: 84-90.
10. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al.: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67: 2643-2648.
11. De Roock W, Claes B, Bernasconi D, et al.: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762.
12. Bardelli A, Siena S,: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28: 1254-1261.
13. Obrand DI, Gordon PH,: Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 1997; 40: 15-24.
14. Tie J, Lipton L, Desai J, et al.: KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res 2011; 17: 1122-1130.
15. Santini D, Loupakis F, Vincenzi B, et al.: High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice. Oncologist 2008; 13: 1270-1275.
16. Cejas P, Lopez-Gomez M, Aguayo C, et al.: KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One 2009; 4: e8199.
17. Greene FL, Page DL, Fleming ID, et al., editors. AJCC Cancer Staging Manual. New York: Springer Verlag. 2002.
18. Lin CC, Lin JK, Lin TC, et al.: The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer. J Surg Oncol 2014; 110: 451-457.
19. Forbes SA, Bindal N, Bamford S, et al.: COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945-D950.
20. Lin CC, Lai YL, Lin TC, et al.: Clinicopathologic features and prognostic analysis of MSI-high colon cancer. Int J Colorectal Dis 2012; 27: 277-286.
21. Boland CR, Thibodeau SN, Hamilton SR, et al.: A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-5257.
22. Fang LT, Lee S, Choi H, et al.: Comprehensive genomic analyses of a metastatic colon cancer to the lung by whole exome sequencing and gene expression analysis. Int J Oncol 2014; 44: 211-221.
23. Smith CG, Fisher D, Claes B, et al.: Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy +/- cetuximab. Clin Cancer Res 2013; 19: 4104-4113.
24. Tran B, Kopetz S, Tie J, et al.: Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011; 117: 4623-4632.
25. Yokota T, Ura T, Shibata N, et al.: BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 2011; 104: 856-862.
26. Artale S, Sartore-Bianchi A, Veronese SM, et al.: Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26: 4217-4219.
27. Benvenuti S, Frattini M, Arena S, et al.: PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat 2008; 29: 284-288.
28. Day FL, Jorissen RN, Lipton L, et al.: PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin Cancer Res 2013; 19: 3285-3296.
29. Nosho K, Kawasaki T, Ohnishi M, et al.: PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008; 10: 534-541.
30. Abubaker J, Bavi P, Al-Harbi S, et al.: Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene 2008; 27: 3539-3545.
31. Velho S, Oliveira C, Ferreira A, et al.: The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005; 41: 1649-1654.
32. Yip WK, Choo CW, Leong VC, et al.: Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia. APMIS 2013; 121: 954-966.
33. Ogino S, Nosho K, Kirkner GJ, et al.: PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009; 27: 1477-1484.
34. Simi L, Pratesi N, Vignoli M, et al.: High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 2008; 130: 247-253.
35. Please check Synopsis for Table of Contents.